RefleXion Announces Initial Close of $105M Fundraising to Commercialize New Cancer Treatment
These new funds will allow RefleXion to extend commercialization of its breakthrough SCINTIX® therapy for treating all stages of indicated solid tumor cancers, including metastatic disease.
- These new funds will allow RefleXion to extend commercialization of its breakthrough SCINTIX® therapy for treating all stages of indicated solid tumor cancers, including metastatic disease.
- “TPG’s support has been foundational in our journey, and we are gratified that they are leading a significant investment in RefleXion.
- “We are delighted to see RefleXion reach a stage where they can accelerate their impact and deliver treatment and outcomes at scale.
- The RefleXion X1 is also cleared for image-guided external-beam radiotherapy for solid tumors located anywhere in the body.